Rezolute, Inc. Files 8-K Current Report
Ticker: RZLT · Form: 8-K · Filed: May 24, 2024 · CIK: 1509261
| Field | Detail |
|---|---|
| Company | Rezolute, Inc. (RZLT) |
| Form Type | 8-K |
| Filed Date | May 24, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, sec-filing
TL;DR
Rezolute filed an 8-K on May 24th for an event on May 21st. Standard disclosure.
AI Summary
Rezolute, Inc. filed an 8-K on May 24, 2024, reporting an event on May 21, 2024. The filing is a current report under Regulation FD and includes financial statements and exhibits. Rezolute, Inc. was formerly known as AntriaBio, Inc. and FITS MY STYLE INC.
Why It Matters
This 8-K filing indicates Rezolute, Inc. is providing updated information to the SEC, which could include material events or financial updates relevant to investors.
Risk Assessment
Risk Level: low — This filing is a routine 8-K current report, typically for disclosures of material events or financial updates, and does not inherently signal high risk.
Key Players & Entities
- Rezolute, Inc. (company) — Registrant
- May 21, 2024 (date) — Earliest event reported
- May 24, 2024 (date) — Filing date
- AntriaBio, Inc. (company) — Former company name
- FITS MY STYLE INC (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing for Rezolute, Inc.?
The 8-K filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating the disclosure of material events.
What was the date of the earliest event reported in this filing?
The date of the earliest event reported was May 21, 2024.
When was this 8-K report filed with the SEC?
This 8-K report was filed on May 24, 2024.
What were Rezolute, Inc.'s previous company names?
Rezolute, Inc. was formerly known as AntriaBio, Inc. and FITS MY STYLE INC.
In which state is Rezolute, Inc. incorporated?
Rezolute, Inc. is incorporated in Nevada.
Filing Stats: 524 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-05-24 14:37:52
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share RZLT Nasdaq Capital Market
Filing Documents
- tm2415552d1_8k.htm (8-K) — 26KB
- tm2415552d1_ex99-1.htm (EX-99.1) — 27KB
- tm2415552d1img001.jpg (GRAPHIC) — 3KB
- 0001104659-24-065073.txt ( ) — 234KB
- rzlt-20240521.xsd (EX-101.SCH) — 3KB
- rzlt-20240521_lab.xml (EX-101.LAB) — 33KB
- rzlt-20240521_pre.xml (EX-101.PRE) — 22KB
- tm2415552d1_8k_htm.xml (XML) — 4KB
01
Item 7.01 Regulation FD Disclosure. On May 21, 2024, Rezolute, Inc. issued a press release to announce positive topline results from a Phase 2 clinic study of RZ402 in 94 patients with diabetic macular edema who are nave to or have received limited anti-vascular growth factor injections. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated May 21, 2024 104 Cover Page Interactive Data File (formatted as inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REZOLUTE, INC. DATE: May 24, 2024 By: /s/Nevan Charles Elam Nevan Charles Elam Chief Executive Officer